-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
ArticleMedicine Guanlan
On November 22, Suntech announced that its self-developed world's first targeting CD38/CD47 double antibody SG2501 has been approved by the US FDA for clinical research
CD38 molecule is a single-chain type II transmembrane glycoprotein, which is widely expressed in hematopoietic cells and non-hematopoietic cell lines, and has many complex and unique biological characteristics and functions
CD47 is a glycoprotein widely expressed on the surface of a variety of cancer cells.
According to the press release, SG2501 is an anti-CD38/CD47 double antibody developed based on the BIMA double antibody platform of Suntech.
It is worth mentioning that, based on the BIMA double antibody platform, Sunkin Bio has also developed a number of "1+1>2" double antibody projects, two of which have been approved for clinical use
Reference
[1] Shangjian Biological announced that the world’s first bi-antibody of its kind, SG2501, was approved by the FDA for clinical use.
[2]Sumgen Bio Official Website.